Fig. 5: CDK1 is a target of miR-34c-3p. | Cancer Gene Therapy

Fig. 5: CDK1 is a target of miR-34c-3p.

From: miR-34c-3p targets CDK1 a synthetic lethality partner of KRAS in non-small cell lung cancer

Fig. 5

a Schematic representation of predicted CDK1mRNA and hsa-miR-34c-3p binding sites in position 1428-1434 of the 3′-UTR. b A549 and HCC827 cells were transiently transfected with CDK1-3′ UTR in the presence of miR-34c-3p or a miRNA negative control (miR-NC). Luciferase activity was evaluated 24 and 48 h after transfection. Experiments were performed in technical triplicates and repeated twice. Bar graphs indicate mean value± SD and the p-value was calculated by Student’s t test. c Western blotting analysis of CDK1 protein after transfection of miR-34c-3p or a negative control in HCC827, A549, and CALU-1 cell lines. Βeta-actin was used as loading control. The experiment was done twice. A representative blot is shown. Bar graphs represent CDK1 densitometry normalized for beta-actin loading. d Western blotting for CDK1 protein after treatment with the GL21.T-miR34c-3p chimaera or GL21.T-miR-NC in A549 and HCC827 cells. Vinculin was used as loading control. The experiment was done twice. A representative blot is shown. e Correlation analysis of CDK1 mRNA and miR-34c in LUSC and LUAD patients from the TCGA data base. We considered 149 out of 167 KRAS-mutated patients with available CDK1 mRNA expression data. Spearman’s rho statistic was used to estimate a rank-based measure of association between the two entities.

Back to article page